At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 33 enrolled
Drug / intervention
E7389drug
Likely dose
E7389 0.25 mg/m² intravenous on Days 1, 8, and 15 of a 28-day cycleAI-extracted
Key inclusion· 7
- ✓Histologically or cytologically confirmed measurable advanced solid tumor that has progressed after standard therapy or for which no standard therapy exists
- ✓Age >18 years
- ✓Karnofsky Performance Status >70%
- ✓Life expectancy >3 months
Key exclusion· 12
- ✕Chemotherapy within 3 weeks (or 6 weeks if nitrosoureas) before E7389 treatment start
- ✕Unrecovered chemotherapy or prior therapy-related toxicity at study entry
- ✕Active anti-coagulant therapy requirement
- ✕Pregnancy, breastfeeding, or women of childbearing potential without adequate contraception
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) in Patients With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating E7389 for Advanced Solid Tumors. Completed, enrolled 33 participants across 2 sites.
Detailed Summary
To determine the maximum tolerated dose of E7389 in patients with advanced solid tumors that have progressed following standard therapy or for which no standard therapy exists.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2003
First PostedSep 2003
Primary CompletionMar 2005
Study CompletionJul 2005
TodayJul 2026
First PostedSep 24, 2003
Enrollment StartSep 1, 2003
Primary CompletionMar 1, 2005
Study CompletionJul 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 22.8 years ago
Interventions
E7389drug
E7389 Dose-escalation starting at 0.25 mg/m\^2 intravenous on Days 1, 8, and 15 of a 28 day cycle.